Osorio et al. generated an anti-CD47 mAb with Fc variants having different affinities for FcγR, and found that treatment with the high-affinity variant highly protected mice bearing CD47+ cancer cells compared with treatment with the low-affinity variant. Here, FCGR2A is linked to cancer.